Physician profile
Indre Doyle
NPI 1417320581
$2,289.75
in general payments reported to CMS, 2019-2025
27 companies · $945 in 2025
The $945 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $190 · 2022: $413 · 2023: $193 · 2024: $549 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $449.70 | 2021-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $377.71 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $311.23 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $178.72 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Insulet Corporation | $156.07 | 2022-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $111.77 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.11 | 2024 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $57.93 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $54.08 | 2023-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $53.72 | 2022-2024 | Gvoke Hypopen |
| Medtronic, INC. | $49.78 | 2021-2024 | Minimed 780g |
| Horizon Therapeutics Plc | $46.85 | 2023 | Tepezza |
| Sequel Med Tech, LLC | $44.73 | 2025 | Twiist |
| Beta Bionics, INC. | $44.15 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $39.89 | 2024 | Cequr Simplicity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.93 | 2024-2025 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $37.17 | 2025 | Dupixent |
| Viatris Specialty LLC | $21.16 | 2025 | Yupelri |
| Recordati_rare_diseases_inc. | $20.74 | 2023 | Isturisa, Signifor Lar |
| Abbvie INC. | $18.31 | 2025 | |
| Amneal Pharmaceuticals LLC | $16.81 | 2025 | Unithroid |
| Rhythm Pharmaceuticals, INC. | $16.76 | 2024 | Imcivree |
| Sanofi-Aventis U.S. LLC | $15.95 | 2021 | |
| Soleno Therapeutics, INC. | $15.94 | 2025 | Vykat Xr |
| Acella Pharmaceuticals, LLC | $14.46 | 2025 | NP Thyroid 60 |
| Lifescan, INC. | $14.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indre Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.